

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/551,607	09/30/2005	Yasuhiko Tabata	17195/005001	6521
22511 OSHA LIANG	7590 06/21/2007		EXAMINER	
1221 MCKINNEY STREET			SAOUD, CHRISTINE J	
SUITE 2800 HOUSTON, TX 77010			ART UNIT	PAPER NUMBER
			1647	
			MAIL DATE	DELIVERY MODE
			06/21/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)
	10/551,607	TABATA ET AL.
Office Action Summary	Examiner	Art Unit
	Christine J. Saoud	1647
The MAILING DATE of this communic Period for Reply	cation appears on the cover sheet wit	th the correspondence address
A SHORTENED STATUTORY PERIOD FO WHICHEVER IS LONGER, FROM THE MA - Extensions of time may be available under the provisions o after SIX (6) MONTHS from the mailing date of this commu - If NO period for reply is specified above, the maximum stat - Failure to reply within the set or extended period for reply w Any reply received by the Office later than three months aft earned patent term adjustment. See 37 CFR 1.704(b).	AILING DATE OF THIS COMMUNIC of 37 CFR 1.136(a). In no event, however, may a re- inication. utory period will apply and will expire SIX (6) MON- vill, by statute, cause the application to become AB	CATION. apply be timely filed THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).
Status		
 Responsive to communication(s) filed This action is FINAL. Since this application is in condition for closed in accordance with the practice 	b)⊠ This action is non-final. or allowance except for formal matte	•
Disposition of Claims		
4) ⊠ Claim(s) <u>1-16</u> is/are pending in the ap 4a) Of the above claim(s) is/are 5) □ Claim(s) is/are allowed. 6) □ Claim(s) is/are rejected. 7) □ Claim(s) is/are objected to. 8) ⊠ Claim(s) <u>1-16</u> are subject to restriction	e withdrawn from consideration.	
Application Papers		
9) The specification is objected to by the 10) The drawing(s) filed on is/are: Applicant may not request that any object Replacement drawing sheet(s) including to 11) The oath or declaration is objected to	a) accepted or b) objected to be the distance of a contraction to the drawing(s) be held in abeyand the correction is required if the drawing(ce. See 37 CFR 1.85(a). s) is objected to. See 37 CFR 1.121(d).
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for a) All b) Some * c) None of: 1. Certified copies of the priority of the certified copies of the priority of the certified copies of the certified copies of application from the Internation * See the attached detailed Office action	locuments have been received. locuments have been received in Ap f the priority documents have been al Bureau (PCT Rule 17.2(a)).	oplication No received in this National Stage
Attachment(s)		
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PT 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	O-948) Paper No(s)	ummary (PTO-413) /Mail Date formal Patent Application

Application/Control Number: 10/551,607

Art Unit: 1647

DETAILED ACTION

Election/Restrictions

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) s 1-16, drawn to an ischemic agent which contains basic fibroblast growth factor.

Group II, claim(s) 1-16, drawn to an ischemic agent which contains vascular endothelial growth factor.

Group III, claim(s) 1-16, drawn to an ischemic agent which contains hepatocyte growth factor.

The inventions listed as Groups I-III do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the common special technical feature of a composition comprising a vascularization induction factor and a gelatin hydrogel is known in the art. According to PCT Rule 13.2, unity of invention exists only when the shared same or corresponding special technical feature defines a contribution over the prior art. Sakakibara et al. teach gelatin micro spheres containing basic fibroblast growth factor (see abstract).

37 CFR 1.475 does not provide for the inclusion of multiple inventions. If multiple products, processes of manufacture or uses are claimed, the first invention of the category first mentioned in the claims will be considered the mane invention (see PCT Article 17(3)(a). Accordingly, the inventions of Groups II and II do not have unity of invention with the composition of Group I.

Application/Control Number: 10/551,607

Art Unit: 1647

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C.103(a) of the other invention.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Art Unit: 1647

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Christine J. Saoud whose telephone number is 571-272-0891. The examiner can normally be reached on Monday-Friday, 6AM-2PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Nickol can be reached on 571-272-0835. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

CHRISTINE J. SAOUD PRIMARY EXAMINER Chustin D. Saoud